Circulating interleukin-4 is associated with a systemic T cell response against tumor-associated antigens in treatment-naïve patients with resectable non-small-cell lung cancer

• Verfasst von: Safi, Seyer [VerfasserIn]
• Verfasst von: Yamauchi, Yoshikane [VerfasserIn]
• Verfasst von: Hoffmann, Hans [VerfasserIn]
• Verfasst von: Weichert, Wilko [VerfasserIn]
• Verfasst von: Jost, Philipp J. [VerfasserIn]
• Verfasst von: Winter, Hauke [VerfasserIn]
• Verfasst von: Muley, Thomas [VerfasserIn]
• Verfasst von: Beckhove, Philipp [VerfasserIn]
• Titel: Circulating interleukin-4 is associated with a systemic T cell response against tumor-associated antigens in treatment-naïve patients with resectable non-small-cell lung cancer
• Verf.angabe: Seyer Safi, Yoshikane Yamauchi, Hans Hoffmann, Wilko Weichert, Philipp J. Jost, Hauke Winter, Thomas Muley and Philipp Beckhove
• E-Jahr: 2020
• Jahr: 24 November 2020
• Umfang: 20 S.
• Fussnoten: Gesehen am 03.03.2022
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2020
• Band/Heft Quelle: 12(2020), 12, Artikel-ID 3496, Seite 1-20
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers12123496
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cytokine
• Sach-SW: immunotherapy
• Sach-SW: lung cancer
• Sach-SW: T cells
• K10plus-PPN: 1788647459

Abstract

Spontaneous T cell responses to tumor-associated antigens (TAs) in the peripheral blood of patients with non-small-cell lung cancer (NSCLC) may be relevant for postoperative survival. However, the conditions underlying these T cell responses remain unclear. We quantified the levels of 27 cytokines in the peripheral blood and tumor tissues from treatment-naïve patients with NSCLC (n = 36) and analyzed associations between local and systemic cytokine profiles and both TA-specific T cell responses and clinical parameters. We defined T cell responders as patients with circulating T cells that were reactive to TAs and T cell nonresponders as patients without detectable TA-specific T cells. TA-specific T cell responses were correlated with serum cytokine levels, particularly the levels of interleukin(IL)-4 and granulocyte colony-stimulating factor (G-CSF), but poorly correlated with the cytokine levels in tumor tissues. Nonresponders showed significantly higher serum IL-4 levels than responders (p = 0.03); the predicted probability of being a responder was higher for individuals with low serum IL-4 levels. In multivariable Cox regression analyses, in addition to IL-4 (hazard ratio (HR) 2.8 (95% confidence interval (CI): 0.78-9.9); p = 0.116), the age-adjusted IL-8 level (HR 3.9 (95% CI: 1.05-14.5); p = 0.042) predicted tumor recurrence. However, this study included data for many cytokines without adjustment for multiple testing; thus, the observed differences in IL-4 or IL-8 levels might be incidental findings. Therefore, additional studies are necessary to confirm these results.